Pfizer acquisition of ADC trailblazer Seagen a worthy investment: GlobalData
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
The patent was granted for creating a green catalyst for one of the world's most significant chemical reactions
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
MoES have identified a potent Anti-cancer molecule named GS/IICT5/6
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
The new powder flow tester can characterize powder flow properties, offering valuable insight for pharmaceutical processing and formulation
Receives regulatory approval for its molecule ‘Selumetinib’ in India
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
Subscribe To Our Newsletter & Stay Updated